Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ALNH
MCID: CST005
MIFTS: 54

Castleman Disease (ALNH)

Categories: Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Castleman Disease

About this section

MalaCards integrated aliases for Castleman Disease:

Name: Castleman Disease 12 53 37 55 44 15
Angiofollicular Ganglionic Hyperplasia 53 44 73
Angiofollicular Lymph Node Hyperplasia 12 53
Angiofollicular Lymph Hyperplasia 12 53
Giant Lymph Node Hyperplasia 12
Angiolymphoid Hyperplasia 73
Castleman's Disease 76
Lymphoid Hamartoma 12
Alnh 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0111157
ICD10 33 D47.Z2
NCIt 50 C3056
SNOMED-CT 68 69484003
KEGG 37 H01479
Sources

Summaries for Castleman Disease

About this section
NIH Rare Diseases : 53 Castleman disease (CD) is a rare condition that affects the lymph nodes and related tissues. There are two main forms: unicentric CD and multicentric CD. Unicentric CD is a "localized" condition that is generally confined to a single set of lymph nodes, while multicentric CD is a "systemic" disease that affects multiple sets of lymph nodes and other tissues throughout the body. The exact underlying cause of CD is currently unknown; however, it is thought to occur sporadically in people with no family history of the condition. Treatment varies based on the form of the condition, the severity of symptoms and whether or not the affected person also has an HIV and/or human herpes virus type 8 (HHV-8) infection. For more specific information about each form of CD, please visit GARD's unicentric Castleman disease and multicentric Castleman disease pages.

MalaCards based summary : Castleman Disease, also known as angiofollicular ganglionic hyperplasia, is related to multicentric castleman disease and human herpesvirus 8. An important gene associated with Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine-cytokine receptor interaction and JAK-STAT signaling pathway. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, b cells and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A lymphoproliferative syndrome characterized by one or more enlarged lymph nodes containing cells with hyaline-vascular, plasmacytic, or mixed appearance microscopically.

Wikipedia : 76 Castleman disease is a group of uncommon lymphoproliferative disorders characterized by lymph node... more...

Sources

Related Diseases for Castleman Disease

About this section

Diseases related to Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 multicentric castleman disease 32.9 BCL6 CRP IL10 IL5 IL6 KRT15
2 human herpesvirus 8 32.3 BCL6 IL6 IL6R
3 poems syndrome 30.6 IL6 VEGFA
4 primary effusion lymphoma 30.2 BCL6 IL6 VEGFA
5 follicular dendritic cell sarcoma 30.1 CR1 CR2 PPL
6 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.8 BCL6 CR2
7 rosai-dorfman disease 29.8 CR2 CRP
8 bronchiolitis obliterans 29.7 IL10 IL6 PPL
9 pericardial effusion 29.7 CRP IL6 VEGFA
10 bronchiolitis 29.6 CRP IL10 IL5 IL6
11 pneumonia 29.6 CRP IL10 IL5 IL6
12 appendicitis 29.6 CRP IL10 IL6
13 systemic lupus erythematosus 29.6 CR1 CR2 CRP IL10 IL6
14 myeloma, multiple 29.5 CRP IL6 IL6R VEGFA
15 rheumatoid arthritis 29.4 CRP IL10 IL6 IL6R VEGFA
16 unicentric castleman disease 12.6
17 angiomatous lymphoid hamartoma 12.4
18 pediatric castleman disease 12.2
19 kaposi sarcoma 12.0
20 sarcoma 10.5
21 glomerulonephritis 10.4
22 membranoproliferative glomerulonephritis 10.4
23 lymphoma 10.4
24 pemphigus 10.3
25 cold agglutinin disease 10.3 CRP IL6
26 cryopyrin-associated periodic syndrome 10.3 CRP IL6
27 paraneoplastic pemphigus 10.3
28 acute cholangitis 10.3 CRP IL6
29 uremic pruritus 10.3 CRP IL6
30 neutrophilia, hereditary 10.2 CRP IL6
31 parapharyngeal meningioma 10.2 CR1 CR2
32 liver inflammatory pseudotumor 10.2 CR2 CRP
33 histiocytic sarcoma 10.2 CR1 CR2
34 relapsing polychondritis 10.2 CRP IL6
35 central nervous system vasculitis 10.2 CRP IL6
36 subacute thyroiditis 10.2 CRP IL6
37 interdigitating dendritic cell sarcoma 10.2 CR1 CR2
38 intussusception 10.2 CRP IL6
39 langerhans cell sarcoma 10.2 CR1 CR2
40 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL5 IL6
41 louse-borne relapsing fever 10.2 CRP IL6
42 bagassosis 10.2 IL5 IL6
43 cecal disease 10.2 CRP IL6
44 histiocytic and dendritic cell cancer 10.2 CR1 CR2
45 reticulum cell sarcoma 10.2 CR1 CR2
46 pyelitis 10.2 CRP IL6
47 chronic meningitis 10.2 CRP IL5
48 ischemic heart disease 10.2 CRP IL6
49 viral pneumonia 10.2 CR1 CRP IL6
50 nail-patella syndrome 10.2

Graphical network of the top 20 diseases related to Castleman Disease:



Diseases related to Castleman Disease
Sources

Symptoms & Phenotypes for Castleman Disease

About this section

MGI Mouse Phenotypes related to Castleman Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 BCL6 CR2 IL10 IL5 IL6 IL6R
2 homeostasis/metabolism MP:0005376 9.91 BCL6 CR2 CRP IL10 IL5 IL6
3 immune system MP:0005387 9.81 BCL6 CR2 CRP IL10 IL5 IL6
4 liver/biliary system MP:0005370 9.43 BCL6 IL10 IL5 IL6 IL6R VEGFA
5 neoplasm MP:0002006 9.1 IL10 IL5 IL6 IL6R PAX5 VEGFA
Sources

Drugs & Therapeutics for Castleman Disease

About this section

Drugs for Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
4 Ganciclovir triphosphate Phase 4,Phase 2
5 Antiviral Agents Phase 4,Phase 2,Early Phase 1
6 Siltuximab Approved, Investigational Phase 2,Phase 1,Early Phase 1 541502-14-1
7
Zidovudine Approved Phase 2 30516-87-1 35370
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
9
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Lenograstim Approved, Investigational Phase 2 135968-09-1
12
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
13
Vincristine Approved, Investigational Phase 2,Phase 1 57-22-7, 2068-78-2 5978
14
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
15
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
16
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
17
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
18
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
19 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
20
Suramin Investigational Phase 2 145-63-1 5361
21
Doxil Approved June 1999 Phase 2,Phase 1 31703
22 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
23 Antibodies Phase 2,Phase 1,Early Phase 1
24 Analgesics Phase 2
25 Immunologic Factors Phase 2,Phase 1,Early Phase 1
26 Antipyretics Phase 2
27 Histamine H1 Antagonists Phase 2
28 Immunoglobulins Phase 2,Phase 1,Early Phase 1
29 Histamine Antagonists Phase 2
30 Pharmaceutical Solutions Phase 2,Phase 1
31 Antiprotozoal Agents Phase 2
32 Antiparasitic Agents Phase 2
33 Anthelmintics Phase 2
34 Reverse Transcriptase Inhibitors Phase 2
35 Anti-HIV Agents Phase 2,Early Phase 1
36 Nucleic Acid Synthesis Inhibitors Phase 2
37 Anti-Retroviral Agents Phase 2,Early Phase 1
38 Antimetabolites Phase 2
39 Hormone Antagonists Phase 2,Phase 1
40 Antineoplastic Agents, Alkylating Phase 2,Phase 1
41 Alkylating Agents Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
45 Anti-Inflammatory Agents Phase 2,Phase 1
46 Immunosuppressive Agents Phase 2,Phase 1
47 Antirheumatic Agents Phase 2,Phase 1
48 glucocorticoids Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 2,Phase 1
50 Angiogenesis Modulating Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Completed NCT01400503 Phase 2 Siltuximab
4 Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease Completed NCT00002652 Phase 2 suramin
5 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
6 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
7 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
8 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
9 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
10 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2 Rituximab
11 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
12 Dose-escalation Study of Oral CX-4945 Unknown status NCT00891280 Phase 1 CX-4945 oral formulation
13 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
14 A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease Completed NCT00412321 Phase 1 CNTO 328
15 An Open-Label Trial of Tocilizumab in Schizophrenia Completed NCT01696929 Phase 1 Tocilizumab
16 Tocilizumab in Schizophrenia Recruiting NCT02874573 Phase 1 Tocilizumab;Normal saline
17 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
18 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
19 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
20 Epithelioid Hemangioma of Bone And Soft Tissue Completed NCT03169595
21 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
22 International Registry for Patients With Castleman Disease Recruiting NCT02817997
23 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
24 Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Recruiting NCT03300830
25 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
26 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
27 Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Terminated NCT02080416 Early Phase 1 Nelfinavir
28 Castleman Disease Collaborative Network Biobank Withdrawn NCT02871050
29 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Castleman Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: castleman disease

Sources

Genetic Tests for Castleman Disease

About this section
Sources

Anatomical Context for Castleman Disease

About this section

MalaCards organs/tissues related to Castleman Disease:

41
Lymph Node, B Cells, Bone, Lung, T Cells, Thyroid, Bone Marrow
Sources

Publications for Castleman Disease

About this section

Articles related to Castleman Disease:

(show top 50) (show all 533)
# Title Authors Year
1
Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis: A case report and 24 months follow up. ( 30479965 )
2019
2
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. ( 29732477 )
2018
3
Paraneoplastic Pemphigus Associated With Castleman Disease Detected by 18F-FDG PET/CT. ( 29561527 )
2018
4
The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 29684500 )
2018
5
Renal failure in pediatric Castleman disease: Four French cases with thrombotic microangiopathy. ( 29603588 )
2018
6
Castleman Disease and Rosai-Dorfman Disease. ( 29217303 )
2018
7
Hepatobiliary and Pancreatic: Obliterative portal venopathy found in Castleman disease variant of POEMS syndrome. ( 29691905 )
2018
8
Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )
2018
9
Castleman disease: delineating the spectrum. ( 29143317 )
2018
10
Castleman Disease Pathogenesis. ( 29157613 )
2018
11
Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. ( 29496669 )
2018
12
The full spectrum of Castleman disease: 273 patients studied over 20A years. ( 29143319 )
2018
13
Castleman disease in the hilum liver mimicking the lymph node metastasis of hepatocellular carcinoma on 18F-FDG PET/CT: A case report. ( 29561464 )
2018
14
Castleman Disease. ( 29157623 )
2018
15
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
16
Clinical and molecular characteristics of unicentric mediastinal Castleman disease. ( 29850111 )
2018
17
Unicentric Castleman Disease. ( 29157620 )
2018
18
Pathology of Castleman Disease. ( 29157618 )
2018
19
Rare Forms of Castleman Disease Mimicking Malignancy: Mesenteric and Pancreatic Involvement. ( 29755906 )
2018
20
Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )
2018
21
Treatment of Idiopathic Castleman Disease. ( 29157622 )
2018
22
The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease. ( 29157616 )
2018
23
The Role of Interleukin-6 in Castleman Disease. ( 29157617 )
2018
24
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. ( 29124835 )
2018
25
(18F)-FDG-PET/MRI of unicentric retroperitoneal Castleman disease in a pediatric patient. ( 29604602 )
2018
26
Diagnosis of Castleman Disease. ( 29157619 )
2018
27
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. ( 29675946 )
2018
28
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
29
Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease. ( 29486963 )
2018
30
Epidemiology of Castleman Disease. ( 29157611 )
2018
31
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case reporta8c. ( 29701172 )
2018
32
Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. ( 30128272 )
2018
33
Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients With Castleman Disease-Associated Paraneoplastic Pemphigus. ( 29389687 )
2018
34
The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. ( 29510921 )
2018
35
Sjögren's and plasma cell variant Castleman disease: a case report. ( 30013261 )
2018
36
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. ( 30074630 )
2018
37
Calcified fibrous pseudotumor with Castleman disease. ( 30101137 )
2018
38
Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. ( 30108026 )
2018
39
Castleman disease versus lymphoma in neck lymph nodes: a comparative study using contrast-enhanced CT. ( 30115111 )
2018
40
Castleman disease. ( 30138514 )
2018
41
ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. ( 30139808 )
2018
42
Hyaline vascular-type unicentric Castleman disease presenting as a subcutaneous nodule in a child. ( 30156317 )
2018
43
Thoracic Paraspinal Castleman Disease in a Young Mexican-American Man with Postcoital Hematuria. ( 30165219 )
2018
44
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. ( 30181172 )
2018
45
Anemia associated with increased hepcidin in two children with Castleman disease. ( 30187597 )
2018
46
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. ( 30203839 )
2018
47
Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature. ( 30228787 )
2018
48
Unusual presentation of an intra-abdominal mass: a rare case of Castleman disease of the greater omentum. ( 30230198 )
2018
49
Castleman disease mimicking systemic lupus erythematosus: A case report. ( 30235674 )
2018
50
Castleman disease of the hyaline vascular variant transforming to POEMS syndrome as endpoint: a case report. ( 30301456 )
2018
Sources

Variations for Castleman Disease

About this section
Sources

Expression for Castleman Disease

About this section
Search GEO for disease gene expression data for Castleman Disease.
Sources

Pathways for Castleman Disease

About this section

Pathways related to Castleman Disease according to KEGG:

37
# Name Kegg Source Accession
1 Cytokine-cytokine receptor interaction hsa04060
2 JAK-STAT signaling pathway hsa04630
3 Hematopoietic cell lineage hsa04640

Pathways related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.72 BCL6 CR1 CRP IL10 IL5 IL6
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.11 BCL6 IL10 IL5 IL6 IL6R VEGFA
3
Pathways in cancer 37
12.65 IL5 IL6 IL6R VEGFA
4
Th17 cell differentiation 37
Show member pathways
 12.4 IL10 IL5 IL6 IL6R
5
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.38 BCL6 CR2 IL5 VEGFA
6
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.16 IL10 IL5 IL6 IL6R
7
Transcriptional misregulation in cancer 37
12.08 BCL6 IL6 PAX5
8
Tuberculosis 37
12.06 CR1 IL10 IL6
9
Colorectal Cancer Metastasis 64
12.01 IL6 IL6R VEGFA
10
FoxO signaling pathway 37
Show member pathways
 11.92 BCL6 IL10 IL6
11
Immune response Lectin induced complement pathway 22
Show member pathways
 11.9 CR1 CR2 CRP
12
Th1 Differentiation Pathway 65
Show member pathways
 11.88 IL10 IL6 IL6R
13
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.88 IL10 IL5 IL6 IL6R
14
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.83 IL10 IL6 IL6R VEGFA
15
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.82 IL10 IL5 IL6
16
HIF-1 signaling pathway 37
11.71 IL6 IL6R VEGFA
17
Jak-Stat Signaling Pathway (sino) 67
11.7 IL10 IL6 IL6R
18
IL6-mediated signaling events 1
Show member pathways
 11.62 CRP IL6 IL6R
19
Interleukin-4 and 13 signaling 66
11.61 BCL6 IL10 IL6 IL6R VEGFA
20
IL4-mediated signaling events 1
11.43 BCL6 IL10 IL5
21
Hematopoietic cell lineage 37
11.34 CR1 CR2 IL5 IL6 IL6R
22
Hepatitis C and Hepatocellular Carcinoma 1
11.32 IL6 IL6R VEGFA
23
Malaria 37
11.27 CR1 IL10 IL6
24
Differentiation Pathway 1
11.23 IL6 IL6R VEGFA
25
Development_Leptin signaling via JAK/STAT and MAPK cascades 22
Show member pathways
 11.12 CRP VEGFA
26
G-protein signaling_RhoB regulation pathway 22
11.05 IL10 IL5 IL6
27
OX40 Pathway 64
11.04 IL10 IL5
28
Cytokines and Inflammatory Response 1
10.9 IL10 IL5 IL6
29
Overview of nanoparticle effects 1
10.89 CRP IL6
30
B Cell Development Pathways 65
10.75 BCL6 CR2 IL10 IL6R PAX5
Sources

GO Terms for Castleman Disease

About this section

Cellular components related to Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-6 receptor complex GO:0005896 8.62 IL6 IL6R

Biological processes related to Castleman Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 CR2 IL10 IL5 IL6
2 regulation of signaling receptor activity GO:0010469 9.77 IL10 IL5 IL6 IL6R VEGFA
3 complement activation, classical pathway GO:0006958 9.75 CR1 CR2 CRP
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.72 IL10 IL5 IL6
5 inflammatory response GO:0006954 9.65 BCL6 CRP IL10 IL5 IL6
6 B cell differentiation GO:0030183 9.63 BCL6 CR2 IL10
7 positive regulation of sprouting angiogenesis GO:1903672 9.61 IL10 VEGFA
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL6 IL6R VEGFA
9 endocrine pancreas development GO:0031018 9.6 IL6 IL6R
10 positive regulation of JAK-STAT cascade GO:0046427 9.59 IL5 IL6
11 positive regulation of chemokine production GO:0032722 9.57 IL6 IL6R
12 interleukin-6-mediated signaling pathway GO:0070102 9.56 IL6 IL6R
13 complement receptor mediated signaling pathway GO:0002430 9.54 CR1 CR2
14 positive regulation of immunoglobulin secretion GO:0051024 9.52 IL5 IL6
15 positive regulation of leukocyte chemotaxis GO:0002690 9.51 IL6 IL6R
16 acute-phase response GO:0006953 9.5 CRP IL6 IL6R
17 positive regulation of cellular component movement GO:0051272 9.49 BCL6 VEGFA
18 negative regulation of lipid storage GO:0010888 9.48 CRP IL6
19 type 2 immune response GO:0042092 9.4 BCL6 IL10
20 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 IL5 IL6 IL6R VEGFA
21 hepatic immune response GO:0002384 9.16 IL6 IL6R
22 cytokine-mediated signaling pathway GO:0019221 9.1 BCL6 IL10 IL5 IL6 IL6R VEGFA

Molecular functions related to Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL10 IL5 IL6 VEGFA
2 interleukin-6 receptor binding GO:0005138 9.16 IL6 IL6R
3 growth factor activity GO:0008083 9.02 IL10 IL5 IL6 IL6R VEGFA
Sources

Sources for Castleman Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....